Skip to main content

Table 5 Laboratory values at baseline (BL) and week-12 (W12)

From: A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers

  All Walk Strength-Walk
BL W12 p BL W12 p BL W12 p
Total Cholesterol (mg/dL) 196 (163–236) 186 (162–215) 0.018 190 (157–229) 180 (151–214) 0.042 217 (174–237) 191 (165–232) n.s.
HDL-Cholesterol (mg/dL) 46 (34–54) 47 (36–56) n.s. 45 (34–55) 47 (35–56) n.s. 46 (33–56) 45 (35–59) n.s.
LDL-Cholesterol (mg/dL) 124 (106–155) 108 (93–139) 0.004 116 (96–148) 103 (89–138) 0.033 147 (120–164) 121 (106–144) 0.031
Triglycerides (mg/dL) 143 (111–201) 131 (93–200) n.s. 142 (101–222) 112 (80–205) n.s. 137 (107–210) 165 (121–283) n.s.
Glucose (mg/dL) 85 (78–92) 82 (79–93) n.s. 85 (74–92) 81 (79–92) n.s. 86 (80–93) 82 (78–93) n.s.
Insulin (mg/dL) 11.8 (7.9-16.5) 13.0 (8.0-16.9) n.s. 10.2 (5.8-17.0) 13.8 (6.6-17.2) n.s. 13.1 (9.9-15.2) 10.3 (8.6-18.8) n.s.
HOMA-Index 2.8 (1.6-3.4) 2.7 (1.7-4.1) n.s. 2.3 (0.9-3.7) 2.8 (1.2-4.1) n.s. 3.0 (2.1-3.3) 2.3 (1.8-5.0) n.s.
HbA1c (%) 5.3 (5.1-5.8) 5.5 (5.3-5.6) n.s. 5.2 (5.0-5.7) 5.3 (5.1-5.6) n.s. 5.5 (5.3-5.9) 5.5 (5.5-6.0) n.s.
CD4+ T-cells/μL 577 (407–726) 559 (445–715) n.s. 485 (365–686) 557 (365–684) n.s. 642 (527–740) 587 (481–796) n.s.
CD8+ T-cells/μL 821 (652–914) 747 (566–975) n.s. 766 (581–872) 743 (632–950) n.s. 916 (783–1349) 747 (561–1090) n.s.
VACS index 12 (5–19) 12 (0–21) n.s. 16 (6–24) 17 (3–22) n.s. 9 (0–12) 10 (0–18) n.s.
  1. Values are expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test
  2. HOMA Homeostasis Model Assessment, VACS Veterans Ageing Cohort Study